Literature DB >> 20102273

When do minority drug-resistant HIV-1 variants have a major clinical impact?

Walid Heneine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20102273     DOI： 10.1086/650545

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  4 in total

1.  Transmitted HIV resistance to first-line antiretroviral therapy in Lima, Peru.

Authors:  Jaime Soria; Marta Bull; Caroline Mitchell; Alberto La Rosa; Sandra Dross; Kelli Kraft; Robert Coombs; Eduardo Ticona; Lisa Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

2.  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.

Authors:  R Karl Malcolm; Ronald S Veazey; Leslie Geer; Deborah Lowry; Susan M Fetherston; Diarmaid J Murphy; Peter Boyd; Ian Major; Robin J Shattock; Per Johan Klasse; Lara A Doyle; Kelsi K Rasmussen; Laurie Goldman; Thomas J Ketas; John P Moore
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

3.  Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks.

Authors:  Bradley G Wagner; J Gerardo Garcia-Lerma; Sally Blower
Journal:  Sci Rep       Date:  2012-03-19       Impact factor: 4.379

4.  Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

Authors:  Karin J Metzner; Christine Leemann; Francesca Di Giallonardo; Christina Grube; Alexandra U Scherrer; Dominique Braun; Herbert Kuster; Rainer Weber; Huldrych F Guenthard
Journal:  PLoS One       Date:  2011-07-06       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.